Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
QuintilesIMS
Healthtrust
Accenture
Fish and Richardson
US Army

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,469,182

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,469,182 protect, and when does it expire?

Patent 6,469,182 protects HALAVEN and is included in one NDA.

This patent has forty patent family members in twenty-one countries.

Summary for Patent: 6,469,182
Title: Intermediates in the preparation of macrocyclic analogs
Abstract:Novel intermediates of the formula ##STR1## They are used in the preparation of macrocyclic analogs.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Palme; Monica H. (San Jose, CA), Seletsky; Boris M. (Andover, MA), Towle; Murray J. (Auburn, NH), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonderry, NH)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:09/843,617
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,469,182

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA   Try a Free Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,469,182

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 502932   Try a Free Trial
Australia 2003284242   Try a Free Trial
Australia 4573999   Try a Free Trial
Australia 762998   Try a Free Trial
Brazil 9911326   Try a Free Trial
Canada 2335300   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Covington
Express Scripts
Mallinckrodt
Cantor Fitzgerald
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.